NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Xenon Pharmaceuticals Inc. XENE
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.5M
EPS · FY25
$-4.36
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-51.8%
Net margin · FY25
-4612.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.5M
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 4612 cents on every revenue dollar this year.
Per share
USD -4.36
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-51.8%
Return on equity, FY2025
ROE
Operating margin-4974.3%
Net margin-4612.1%
Return on assets-48.3%
Each USD of equity lost 52 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−25.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−7.4%
−25.3%
−7.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years+128.5%
Change, 10 years+456.2%
The share count grew 129% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 633.2M
total assets, end of FY2025
Total assetsUSD 633.2M
EquityUSD 581.8M
CashUSD 199.2M
Current ratio13.42×
Equity funds 92% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
0.0
0.0
−0.0
Income tax $B
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
0.0
0.0
0.0
Net income $B
−0.3
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
EPS, diluted $
−4.36
−3.01
−2.73
−2.06
−1.77
−0.81
−1.54
−1.63
−1.72
−1.48
−1.10
3.28
1.91
−3.24
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−51.8
−27.8
−22.1
−19.7
−21.9
−21.9
−42.6
−49.6
−61.5
−36.8
−23.5
·
·
·
Shares out B
0.08
0.08
0.08
0.06
0.05
0.04
0.03
0.03
0.02
0.02
0.01
0.01
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
40 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed